Neven P

No ORCID on file · 7 papers in corpus · active 1993-2023

Study types

  • review 2
  • other 1

Condition tags

  • endometriosis 3
2023
Annals of medicine and surgery (2012) ·doi:10.1097/ms9.0000000000000660

Ten to fifty percent of women with advanced or recurrent ovarian cancer develop malignant bowel obstruction (MBO). We described the management and examined the complications and survival of MBO in primary epithelial tubo-ovarian cancer pati…

2022
Nature communications ·doi:10.1038/s41467-022-33052-y

Since a detailed inventory of endothelial cell (EC) heterogeneity in breast cancer (BC) is lacking, here we perform single cell RNA-sequencing of 26,515 cells (including 8433 ECs) from 9 BC patients and compare them to published EC taxonomi…

2016
Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

ObjectiveClinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with …

2008
Breast care (Basel, Switzerland) ·doi:10.1159/000136105

BACKGROUND: Mammary tuberculosis is rare in the Western world. It has no defined clinical or imaging features, and has to be differentiated from breast cancer and an abscess. CASE REPORT: We present a case of mammary tuberculosis combined w…

review 2004
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2003.03.001

For several decades, endometriosis has been suspected of playing a role in the aetiology of ovarian cancer. The literature concerning a possible histogenesis of ovarian cancer from benign endometriosis is reviewed in this chapter. Epidemiol…

review 2002
Maturitas ·doi:10.1016/s0378-5122(02)00031-2

Unopposed estrogens for treating menopausal symptoms were extensively used when epidemiological findings associated them with an increased endometrial cancer risk. Adding progestogens reverse this side effect efficiently but patient, dose, …

other 1993
Cancer ·doi:10.1002/1097-0142(19930615)71:12<4124::aid-cncr2820711252>3.0.co;2-p

BACKGROUND: The presence of urinary excretion products of human chorionic gonadotropin (hCG) has been proposed as a tumor marker. To ascertain the clinical value in gynecologic cancers, the authors studied 612 nonpregnant women. METHODS: T…